Novo Nordisk (NOV) Stock Forecast & Price Target

Compare

523 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NOV Analyst Ratings

Moderate Buy

6 Buy

6 Hold

1 Sell

Based on 13 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NOV Stock 12 Month Forecast

Average Price Target

€58.85

▲(28.14% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is €58.85 with a high forecast of €80.30 and a low forecast of €45.50. The average price target represents a 28.14% change from the last price of €45.93.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"€40","56":"€56","72":"€72","88":"€88","104":"€104"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80.3022,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€80.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.85482075,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€58.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.50458,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€45.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,56,72,88,104],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.07,52.395553846153845,54.72110769230769,57.046661538461535,59.37221538461539,61.697769230769225,64.02332307692308,66.34887692307692,68.67443076923077,70.99998461538462,73.32553846153846,75.65109230769231,77.97664615384615,{"y":80.3022,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.07,50.74575544230769,51.42151088461539,52.09726632692308,52.77302176923077,53.44877721153846,54.12453265384615,54.80028809615385,55.47604353846154,56.15179898076923,56.827554423076926,57.503309865384615,58.17906530769231,{"y":58.85482075,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.07,49.71881384615384,49.36762769230769,49.016441538461535,48.665255384615385,48.31406923076923,47.96288307692308,47.61169692307692,47.26051076923077,46.90932461538461,46.55813846153846,46.206952307692305,45.85576615384615,{"y":45.50458,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":103.754,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.351,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.837,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.418,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.367,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.034,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.389,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.666,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.667,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.842,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.168,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€80.30

Average Price Target€58.85

Lowest Price Target€45.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Weston

UBS

€45.5

Hold

-0.93%

Downside

Reiterated

10/22/25

UBS Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Emmanuel Papadakis

Deutsche Bank

€80.3

Buy

74.84%

Upside

Reiterated

10/22/25

Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

Florent Cespedes

Bernstein

€72.27

Buy

57.35%

Upside

Reiterated

10/22/25

Bernstein Remains a Buy on Novo Nordisk (0QIU)

Richard Vosser

J.P. Morgan

€66.92

Buy

45.70%

Upside

Reiterated

10/17/25

J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

€52.46

Buy

14.23%

Upside

Reiterated

10/01/25

Goldman Sachs Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

David Evans

Kepler Capital

€68.26

Buy

48.61%

Upside

Reiterated

09/19/25

Kepler Capital Remains a Buy on Novo Nordisk (0QIU)

Sachin Jain

Bank of America Securities

€50.19

Hold

9.27%

Upside

Reiterated

09/18/25

Cautious Outlook for Novo Nordisk Amid Uncertain Pipeline Outcomes and Growth Challenges

Kerry Holford

Berenberg Bank

€81.64→€56.88

Buy

23.84%

Upside

Upgraded

09/17/25

Positive Report for Novo Nordisk (0QIU) from Berenberg Bank

Nico Chen

DBS

€45.5

Hold

-0.93%

Downside

Upgraded

08/22/25

Novo Nordisk upgraded to Hold from Sell at DBS BankNovo Nordisk upgraded to Hold from Sell at DBS Bank

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

08/08/25

DZ BANK AG Keeps Their Hold Rating on Novo Nordisk (0QIU)

Benjamin Jackson CFA

Jefferies

€55.54

Sell

20.93%

Upside

Reiterated

08/06/25

Jefferies Sticks to Their Sell Rating for Novo Nordisk (0QIU)

Emily Field

Barclays

€50.19

Hold

9.27%

Upside

Reiterated

08/04/25

Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)

Martial Descoutures

Oddo BHF

€62.23

Hold

35.50%

Upside

Downgraded

07/30/25

Novo Nordisk downgraded to Neutral from Outperform at Oddo BHFNovo Nordisk downgraded to Neutral from Outperform at Oddo BHF

Thibault Boutherin

Morgan Stanley

€73.61

Hold

60.27%

Upside

Reiterated

06/23/25

Morgan Stanley Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Eric Le Berrigaud

Stifel Nicolaus

€104.39→€93.69

Hold

103.98%

Upside

Downgraded

03/03/25

Novo Nordisk downgraded to Hold from Buy at StifelNovo Nordisk downgraded to Hold from Buy at Stifel

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Weston

UBS

€45.5

Hold

-0.93%

Downside

Reiterated

10/22/25

UBS Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Emmanuel Papadakis

Deutsche Bank

€80.3

Buy

74.84%

Upside

Reiterated

10/22/25

Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

Florent Cespedes

Bernstein

€72.27

Buy

57.35%

Upside

Reiterated

10/22/25

Bernstein Remains a Buy on Novo Nordisk (0QIU)

Richard Vosser

J.P. Morgan

€66.92

Buy

45.70%

Upside

Reiterated

10/17/25

J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

€52.46

Buy

14.23%

Upside

Reiterated

10/01/25

Goldman Sachs Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

David Evans

Kepler Capital

€68.26

Buy

48.61%

Upside

Reiterated

09/19/25

Kepler Capital Remains a Buy on Novo Nordisk (0QIU)

Sachin Jain

Bank of America Securities

€50.19

Hold

9.27%

Upside

Reiterated

09/18/25

Cautious Outlook for Novo Nordisk Amid Uncertain Pipeline Outcomes and Growth Challenges

Kerry Holford

Berenberg Bank

€81.64→€56.88

Buy

23.84%

Upside

Upgraded

09/17/25

Positive Report for Novo Nordisk (0QIU) from Berenberg Bank

Nico Chen

DBS

€45.5

Hold

-0.93%

Downside

Upgraded

08/22/25

Novo Nordisk upgraded to Hold from Sell at DBS BankNovo Nordisk upgraded to Hold from Sell at DBS Bank

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

08/08/25

DZ BANK AG Keeps Their Hold Rating on Novo Nordisk (0QIU)

Benjamin Jackson CFA

Jefferies

€55.54

Sell

20.93%

Upside

Reiterated

08/06/25

Jefferies Sticks to Their Sell Rating for Novo Nordisk (0QIU)

Emily Field

Barclays

€50.19

Hold

9.27%

Upside

Reiterated

08/04/25

Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)

Martial Descoutures

Oddo BHF

€62.23

Hold

35.50%

Upside

Downgraded

07/30/25

Novo Nordisk downgraded to Neutral from Outperform at Oddo BHFNovo Nordisk downgraded to Neutral from Outperform at Oddo BHF

Thibault Boutherin

Morgan Stanley

€73.61

Hold

60.27%

Upside

Reiterated

06/23/25

Morgan Stanley Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Eric Le Berrigaud

Stifel Nicolaus

€104.39→€93.69

Hold

103.98%

Upside

Downgraded

03/03/25

Novo Nordisk downgraded to Hold from Buy at StifelNovo Nordisk downgraded to Hold from Buy at Stifel

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

1 Month

xxx

Success Rate

38/62 ratings generated profit

Average Return

+1.32%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.29% of your transactions generating a profit, with an average return of +1.32% per trade.

3 Months

xxx

Success Rate

38/62 ratings generated profit

Average Return

+2.66%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.29% of your transactions generating a profit, with an average return of +2.66% per trade.

1 Year

Richard VosserJ.P. Morgan

Success Rate

42/62 ratings generated profit

Average Return

+15.98%

reiterated a buy rating 11 days ago

Copying Richard Vosser's trades and holding each position for 1 Year would result in 67.74% of your transactions generating a profit, with an average return of +15.98% per trade.

2 Years

xxx

Success Rate

34/62 ratings generated profit

Average Return

+15.95%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 54.84% of your transactions generating a profit, with an average return of +15.95% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOV Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NOV has received 25 Buy Ratings, 23 Hold Ratings, and 1 Sell Ratings. NOV average Analyst price target in the past 3 months is 58.85.

Each month's total comprises the sum of three months' worth of ratings.

NOV Financial Forecast

NOV Earnings Forecast

Next quarter’s earnings estimate for NOV is €0.67 with a range of €0.54 to €0.83. The previous quarter’s EPS was €0.80. NOV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year NOV has Preformed in-line its overall industry.

NOV Sales Forecast

Next quarter’s sales forecast for NOV is €10.27B with a range of €9.99B to €10.53B. The previous quarter’s sales results were €10.29B. NOV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year NOV has Preformed in-line its overall industry.

NOV Stock Forecast FAQ

What is DE:NOV’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk’s 12-month average price target is 58.85.

What is DE:NOV’s upside potential, based on the analysts’ average price target?

Novo Nordisk has 28.14% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novo Nordisk a Buy, Sell or Hold?

Novo Nordisk has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 6 hold ratings and 1 sell ratings.

What is Novo Nordisk’s share price target?

The average share price target for Novo Nordisk is 58.85. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €80.30 ,and the lowest forecast is €45.50. The average share price target represents 28.14% Increase from the current price of €45.93.

What do analysts say about Novo Nordisk?

Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Novo Nordisk?

To buy shares of DE:NOV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Novo Nordisk (NOV) Stock Forecast & Price Target

NOV Analyst Ratings

NOV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

NOV Analyst Recommendation Trends

NOV Financial Forecast

NOV Earnings Forecast

NOV Sales Forecast

NOV Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts